ArticleVaccines2020
Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC.
Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05409196 (Phase 1 Two Stage Randomized, Double-blind, Placebo Controlled Dose- and Schedule Ranging Trial to Assess the Acute Safety, Tolerability, and Immunogenicity of a Live, Attenuated Shigella/ETEC Combination Vaccine Delivered Orally to Healthy Adults Age 18 to 45 Years Old), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1 Two Stage Randomized, Double-blind, Placebo Controlled Dose- and Schedule Ranging Trial to Assess the Acute Safety, Tolerability, and Immunogenicity of a Live, Attenuated Shigella/ETEC Combination Vaccine Delivered Orally to Healthy Adults Age 18 to 45 Years Old
Who cites it
29 citing papers in PubMed, 39 citations in OpenAlex.
- Trial
- Review
- Vaccine Candidates Designed to Prevent Enterotoxigenic Escherichia coli Diarrhoea: A Scoping Review of Clinical Trials Evaluating Vaccine Candidates in Development.Tropical medicine & international health : TM & IH · 2026Article
- Research progress on multivalent genetically engineered vaccines against enterotoxigenicFrontiers in immunology · 2026Review
- Compatibility and Stability of aVaccines · 2025Article
- Recent progress in enterotoxigenicInfection and immunity · 2025Review
- Shigellosis.Lancet (London, England) · 2025Review
- Conserved antigens for enteric vaccines.Vaccine · 2025Review
- Review
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
- The association between the gut microbiome and antituberculosis drug-induced liver injury.Frontiers in pharmacology · 2025Article
- Effect of Fusion to the LTB Carrier Protein on Coronavirus Spike Protein Vaccine Candidates Produced in Maize.Viruses · 2024Article
- A RecombinantInternational journal of molecular sciences · 2024Article
- Facilitating the development of urgently required combination vaccines.The Lancet. Global health · 2024Review
- Special Issue on EnterotoxigenicMicroorganisms · 2024Article
- Review
- Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024Review
- Protein-based vaccine candidate MecVax broadly protects against enterotoxigenicInfection and immunity · 2023Article
- Anti-Toxin Responses to Natural EnterotoxigenicMicroorganisms · 2023Article
- Development of themSphere · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.